Second-line dovitinib in metastatic endometrial cancer
Mené sur 248 patientes atteintes d'un cancer de l'endomètre de stade métastatique ou avancé, cet essai international de phase II évalue l'efficacité, du point de vue de la survie sans progression à 18 semaines, et la toxicité du dovitinib pour un traitement de deuxième ligne, en fonction de la présence ou de l'absence d'un gène FGFR2 muté
Cytotoxic chemotherapy is standard of care for patients with metastatic endometrial cancer, but options are few and often palliative. Taxanes, anthracyclines, and platinum agents are the main drug classes with benefit, and agents that work complementarily to conventional chemotherapeutics are badly needed. Such a drug would ideally work through distinct mechanisms to avoid dose-limiting clinical toxicities common to cytotoxic regimens in the setting of incurable disease. In this context, Gottfried Konecny and colleagues1 assess the compound dovitinib in patients with metastatic endometrial cancer, published in The Lancet Oncology.
The Lancet Oncology , commentaire, 2014